Most Clicked StoriesMore >


EMA advice improves rates of clinical trial approvals

DIA Global SmartBrief | Apr 21, 2015

Approval rates increased and approval time was reduced for new medications when drugmakers followed scientific advice on clinical trial design from the European Medicines Agency, according to a study conducted by the EMA and its Scientific Advice Working Party and published in Nature Reviews Drug Discovery. Success rates increased to 84% when drugmakers used an approved trial design and rose to 86% when EMA-recommended revisions were made to correct a flawed design. Incorporating EMA advice also resulted in shorter review periods by the Committee for Medicinal Products for Human Use. PharmaTimes (U.K.) (04/20)


Counterfeit, substandard drugs are global danger

DIA Global SmartBrief | Apr 23, 2015

FDA to use EHRs to evaluate drugs' postmarket safety

DIA Global SmartBrief | Apr 23, 2015

WHO calls for greater transparency in clinical trials

DIA Global SmartBrief | Apr 21, 2015

Roche breast cancer drug shows early positive results

DIA Global SmartBrief | Apr 23, 2015

Experimental drug appears to benefit damaged myelin

DIA Global SmartBrief | Apr 21, 2015

Taiwan to implement changes to medtech registration, approval

DIA Global SmartBrief | Apr 21, 2015

Specialty drugs represent 42% of late-stage pipeline

DIA Global SmartBrief | Apr 23, 2015

China API firm receives FDA warning letter

DIA Global SmartBrief | Apr 23, 2015

DIA works to globally advance the science of safety

DIA Global SmartBrief | Apr 23, 2015


Find DIA Global SmartBrief Issues by Date:



DIA News More >


DIA works to globally advance the science of safety

DIA Global SmartBrief | Apr 23, 2015

DIA 2015 51st Annual Meeting

DIA Global SmartBrief | Apr 21, 2015

DIA China 7th Annual Meeting

DIA Global SmartBrief | Apr 16, 2015

Risk-based monitoring sessions at DIA 2015

DIA Global SmartBrief | Apr 14, 2015

Special opportunity for government representatives

DIA Global SmartBrief | Apr 09, 2015




Sign up for DIA Global SmartBrief



Designed specifically for the global drug development professional, the DIA Global SmartBrief is a FREE, twice weekly e-mail newsletter. By providing the latest need-to-know industry news and information, the DIA Global SmartBrief saves you time and keeps you smart. Learn more